Skip to main content

Vaximm is using AI to develop cancer vaccines

| News

Vaximm is using AI to develop cancer vaccines


Basel-based biotech company Vaximm has agreed a collaboration with IT company NEC. Vaximm wants to develop personalized cancer vaccines using NEC’s artificial intelligence (AI)-based prediction system.

Vaccine (Img: PhotoLizM/Pixabay)

According to a press release by Vaximm, Vaximm and NEC have agreed to cooperate on a non-exclusive basis. As part of the collaboration, NEC will make an equity investment in Vaximm. In addition, the Tokyo-based IT company will provide funding for a Phase I clinical trial for personalized neoantigen cancer vaccines.

The two partners want to develop the vaccines through the agreed collaboration. Vaximm will provide its experience in developing oral T-cell immunotherapies for patients, while NEC has developed a neoantigen prediction system based on state-of-the-art artificial intelligence (AI) technology, which is to be utilized in the development of cancer vaccines. Vaximm will manage the clinical trial scheduled for the coming year. NEC has secured the development and commercialization rights to the program worldwide, except for China and other Asian territories, which also apply to Japan.

Heinz Lubenau, PhD, Chief Operating Officer and Co-Founder of Vaximm, said: “NEC’s novel AI technology will enable not only the identification but also the prioritization of neoantigens from each patient. Once the list of neoantigens is available, we will be able to apply our technology to quickly produce a personalized vaccine. “

Vaximm is headquartered in the Technology Park, Basel. The location will be pleased to hear another success story from one of its companies based there. This means an extension of the cooperation between NBE Therapeutics and the Czech biotech company Sotio. NBE Therapeutics specializes in developing antibody drug conjugate products for cancer treatment. The two companies want to work together to develop next-generation antibody drug conjugates. Sotio has now exercised the option for developing a second drug candidate. NBE Therapeutics will also be able to use its in-house platform for this, while Sotio has the corresponding commercial rights. The exercise of the option by Sotio will give NBE the right to receive certain payments.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.